ENGN

enGene Therapeutics Inc. ENGN

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-32.50M

Quarter to Jul 31

Free cash flow

$-18.95M

Quarter to Jul 31

Top Institutional Holders

as of Q2 2026
$88.05M total
FCPM III SERVICES B.V.
$17.50M0.0%
BML Capital Management, LLC
$11.54MNew
Siren, L.L.C.
$10.82M+19.1%
PERCEPTIVE ADVISORS LLC
$8.34M-17.3%
AMERIPRISE FINANCIAL INC
$4.63MNew
Nextech Invest, Ltd.
$4.02M0.0%
ADAR1 Capital Management, LLC
$3.64M+1474.6%
Vestal Point Capital, LP
$2.88M-23.0%
ACORN CAPITAL ADVISORS, LLC
$2.20MNew
Peapod Lane Capital LLC
$1.91MNew
BALYASNY ASSET MANAGEMENT L.P.
$1.74M-12.3%
MILLENNIUM MANAGEMENT LLC
$1.67M+0.7%
Omega Fund Management, LLC
$1.52M0.0%
RENAISSANCE TECHNOLOGIES LLC
$1.44M+431.5%
SR ONE CAPITAL MANAGEMENT, LP
$1.29M0.0%
CITADEL ADVISORS LLC
$1.24M+366.2%
Affinity Asset Advisors, LLC
$1.04M-1.7%
UBS Group AG
$880.7K+3810.9%
Quadrature Capital Ltd
$827.1K+1314.5%
Eversept Partners, LP
$812.4K-8.0%
Kynam Capital Management, LP
$792.1K-66.3%
Seven Fleet Capital Management LP
$711.1KNew
JANE STREET GROUP, LLC
$661.7K+145.2%
Rangeley Capital, LLC
$527.8KNew
BARCLAYS PLC
$488.8KNew
See all 70 institutional holders →

What's Driving ENGN's Business? Latest 10-Q Breakdown

15/15 datapoints verified

AI-extracted from the 10-Q filed 2026-09-08 — Q3 FY2026 (quarter ended July 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Clinical-stage biotech enGene reported $20.1M R&D and $13.9M G&A expenses for Q3 2026, reducing workforce by 50% to preserve $266.3M in cash and plan Q4 2026 BLA submission for detalimogene.

Biggest Revenue Drivers

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Net Income

Q3 2026
EDGAR

EPS (Diluted)

Q3 2026
EDGAR

ROIC

Q3 2026
EDGAR

Free Cash Flow

Q3 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ENGN

Earnings Per Share

13fpro.ai/company/ENGN

Loading ratio trend…

ENGN insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About enGene Therapeutics Inc. (ENGN): stock profile, AI score and financials

enGene Therapeutics Inc. (ENGN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ENGN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q3 2026), enGene Therapeutics Inc. reports net income of $-32.5M, free cash flow of $-18.9M. Top institutional holders of ENGN by reported 13-F value include FCPM III SERVICES B.V., BML Capital Management, Siren, L.L.C., based on the most recent SEC filings. ENGN trades on the Nasdaq exchange and files with the SEC under CIK 1980845. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for enGene Therapeutics Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1980845 →